Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBEZERRA-SOUZA, Adriana
dc.contributor.authorFERNANDEZ-GARCIA, Raquel
dc.contributor.authorRODRIGUES, Gabriela F.
dc.contributor.authorBOLAS-FERNANDEZ, Francisco
dc.contributor.authorLAURENTI, Marcia Dalastra
dc.contributor.authorPASSERO, Luiz Felipe
dc.contributor.authorLALATSA, Aikaterini
dc.contributor.authorSERRANO, Dolores R.
dc.identifier.citationPHARMACEUTICS, v.11, n.7, article ID 353, 14p, 2019
dc.description.abstractLeishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. These treatment realities justify the search for new effective drugs, repurposing existing licensed drugs towards safer and non-invasive cost-effective medicines for VL. In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised using design of experiments, and then were spray-dried onto porous colloidal silica carriers to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties (angle of repose <10 degrees) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe administration of butenafine as a cost-effective and readily scalable repurposed medicine for VL.eng
dc.description.sponsorshipUnion Iberoamericana de Universidades [ENF03-2017]
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/00468-0, 2017/09405-4]
dc.subjectsolid SNEDDSeng
dc.subjectspray dryingeng
dc.subjectdesign of experimentseng
dc.subject.otherdrug-delivery systemseng
dc.titleRepurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasiseng
dc.rights.holderCopyright MDPIeng
dc.subject.wosPharmacology & Pharmacyeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Raquel:Univ Complutense, Dept Pharmaceut & Food Technol, Sch Pharm, Ave Complutense, E-28040 Madrid, Spain; Univ Complutense, IUFI, Sch Pharm, Ave Complutense, E-28040 Madrid, Spain, Francisco:Univ Complutense Madrid, Dept Microbiol & Parasitol, Sch Pharm, Plaza Ramon y Cajal S-N, E-28040 Madrid, Spain, Aikaterini:Univ Portsmouth, Sch Pharm & Biomed Sci, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England, Dolores R.:Univ Complutense, Dept Pharmaceut & Food Technol, Sch Pharm, Ave Complutense, E-28040 Madrid, Spain; Univ Complutense, IUFI, Sch Pharm, Ave Complutense, E-28040 Madrid, Spain
hcfmusp.relation.referenceAnton N, 2011, PHARM RES-DORDR, V28, P978, DOI 10.1007/s11095-010-0309-1eng
hcfmusp.relation.referenceAraujo-Santos T, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000873eng
hcfmusp.relation.referenceBarak E, 2005, MOL BIOCHEM PARASIT, V141, P99, DOI 10.1016/j.molbiopara.2005.02.004eng
hcfmusp.relation.referenceBetatek Inc, 2012, INSTR SUP SUPP MICReng
hcfmusp.relation.referenceBezerra-Souza A, 2016, PARASITOL INT, V65, P702, DOI 10.1016/j.parint.2016.08.003eng
hcfmusp.relation.referenceDantas-Torres F, 2006, MEM I OSWALDO CRUZ, V101, P117, DOI 10.1590/S0074-02762006000100024eng
hcfmusp.relation.referencePassero LFD, 2009, PARASITOL RES, V105, P1741, DOI 10.1007/s00436-009-1614-7eng
hcfmusp.relation.referenceDorlo TPC, 2012, J ANTIMICROB CHEMOTH, V67, P2576, DOI 10.1093/jac/dks275eng
hcfmusp.relation.referenceElnaggar YSR, 2009, INT J PHARMACEUT, V380, P133, DOI 10.1016/j.ijpharm.2009.07.015eng
hcfmusp.relation.referenceFood and Drug Administration (FDA), REV EV PHARM TOX DATeng
hcfmusp.relation.referenceGoh HP, 2018, INT J PHARMACEUT, V547, P133, DOI 10.1016/j.ijpharm.2018.05.059eng
hcfmusp.relation.referenceGosh S., 2014, J APPL PHARM SCI, V4, P123eng
hcfmusp.relation.referenceGraul AI, 2010, DRUG NEWS PERSPECT, V23, P7, DOI 10.1358/dnp.2010.23.1.1440373eng
hcfmusp.relation.referenceHumberstone AJ, 1997, ADV DRUG DELIVER REV, V25, P103, DOI 10.1016/S0169-409X(96)00494-2eng
hcfmusp.relation.referenceImada C, 2015, PHARM RES-DORDR, V32, P2595, DOI 10.1007/s11095-015-1646-xeng
hcfmusp.relation.referenceKaur G, 2014, J PARASITOL RES, V2014, P1eng
hcfmusp.relation.referenceKhan AA, 2013, INT J NANOMED, V8, P2733, DOI 10.2147/IJN.S41521eng
hcfmusp.relation.referenceLaison R., 1988, MICROBIOLOGY MICROBIeng
hcfmusp.relation.referenceLaurenti MD, 2009, SCAND J IMMUNOL, V70, P389, DOI 10.1111/j.1365-3083.2009.02310.xeng
hcfmusp.relation.referenceLavoie F, 2002, PHARMACEUT RES, V19, P887, DOI 10.1023/A:1016125420577eng
hcfmusp.relation.referenceLeonaviciute G, 2017, EUR J PHARM BIOPHARM, V112, P51, DOI 10.1016/j.ejpb.2016.11.019eng
hcfmusp.relation.referenceFernandez OL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002871eng
hcfmusp.relation.referenceMaher S, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010041eng
hcfmusp.relation.referencePerez-Victoria FJ, 2006, DRUG RESIST UPDATE, V9, P26, DOI 10.1016/j.drup.2006.04.001eng
hcfmusp.relation.referencePorter CJH, 2008, ADV DRUG DELIVER REV, V60, P673, DOI 10.1016/j.addr.2007.10.014eng
hcfmusp.relation.referenceRittig MG, 2000, PARASITOL TODAY, V16, P292, DOI 10.1016/S0169-4758(00)01692-6eng
hcfmusp.relation.referenceRoberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3eng
hcfmusp.relation.referenceRYDER NS, 1992, BRIT J DERMATOL, V126, P2, DOI 10.1111/j.1365-2133.1992.tb00001.xeng
hcfmusp.relation.referenceSantos DO, 2008, PARASITOL RES, V103, P1, DOI 10.1007/s00436-008-0943-2eng
hcfmusp.relation.referenceSeifert K, 2010, J ANTIMICROB CHEMOTH, V65, P508, DOI 10.1093/jac/dkp500eng
hcfmusp.relation.referenceSerrano DR, 2017, J DRUG DELIV SCI TEC, V42, P75, DOI 10.1016/j.jddst.2017.04.017eng
hcfmusp.relation.referenceSerrano DR, 2017, CURR TOP MED CHEM, V17, P2888, DOI 10.2174/1568026617666170719164318eng
hcfmusp.relation.referenceSerrano DR, 2013, INT J PHARMACEUT, V447, P38, DOI 10.1016/j.ijpharm.2013.02.038eng
hcfmusp.relation.referenceShen SH, 2017, INT J NANOMED, V12, P4085, DOI 10.2147/IJN.S132780eng
hcfmusp.relation.referenceSilveira FT, 2010, T ROY SOC TROP MED H, V104, P529, DOI 10.1016/j.trstmh.2010.05.002eng
hcfmusp.relation.referenceSingal A, 2008, EXPERT OPIN DRUG MET, V4, P999, DOI [10.1517/17425255.4.7.999 , 10.1517/17425250802190358]eng
hcfmusp.relation.referenceSmith L, 2018, MOL PHARMACEUT, V15, P2570, DOI 10.1021/acs.molpharmaceut.8b00097eng
hcfmusp.relation.referenceSoto J, 2001, Clin Infect Dis, V33, pE57, DOI 10.1086/322689eng
hcfmusp.relation.referenceStutz A, 1988, Ann N Y Acad Sci, V544, P46, DOI 10.1111/j.1749-6632.1988.tb40388.xeng
hcfmusp.relation.referenceTatham LM, 2015, THER DELIV, V6, P469, DOI [10.4155/TDE.15.4, 10.4155/tde.15.4]eng
hcfmusp.relation.referenceTobinick EL, 2009, DRUG NEWS PERSPECT, V22, P119, DOI 10.1358/dnp.2009.22.2.1303818eng
hcfmusp.relation.referenceUnited States Pharmacopeia (USP), 2008, USP 41 NF36 POWD FLOeng
hcfmusp.relation.referenceUnited States Pharmacopeia (USP), 2006, USP 41 NF36 POWD FLOeng
hcfmusp.relation.referenceWorld Health Organization (WHO), LEISHM DIS EPeng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - LIM/50
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
art_BEZERRA-SOUZA_Repurposing_Butenafine_as_An_Oral_Nanomedicine_for_Visceral_2019.PDFpublishedVersion (English)1.76 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.